Connective Tissue Disease : Current Concepts - 21/11/18

Doi : 10.1016/j.det.2018.07.006

Anthony P. Fernandez, MD, PhD
Departments of Dermatology and Pathology, Cleveland Clinic Lerner College of Medicine, 9500 Euclid Avenue A61, Cleveland, OH 44195, USA

Résumé

Connective tissue diseases often prominently affect the skin, requiring dermatologists to play an important role in diagnosis and treatment of these patients. Herein we describe updates on the pathogenesis, clinical features, and treatment of 4 major connective tissue diseases: dermatomyositis, cutaneous lupus erythematosus, limited scleroderma (morphea), and cutaneous vasculitis. Many of these updates promise to improve clinical care of patients who suffer from dermatologic involvement of these diseases and are the result of research performed by dermatologists who have expertise in these conditions.

Le texte complet de cet article est disponible en PDF.

Keywords : Connective tissue disease, Dermatomyositis, Cutaneous lupus erythematosus, Morphea, Cutaneous vasculitis

Plan

Key points

Introduction

Dermatomyositis

Cutaneous lupus erythematosus

Morphea

Cutaneous vasculitis

Summary

Disclosure Statement: Dr A.P. Fernandez is a Principal Investigator and receives funding from Mallinckrodt (Efficacy and Safety of H.P. Acthar gel for the treatment of refractory cutaneous manifestations of dermatomyositis; ClinicalTrials.gov identifier NCT02245841) and Pfizer (A Phase 2a, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Pf-06823859 In Adult Subjects With Dermatomyositis; ClinicalTrials.gov identifier NCT03181893) for dermatomyositis research and is a consultant for Celgene. He also is an investigator for the ARAMIS (ClinicalTrials.gov identifier NCT02939573) and CUTIS (ClinicalTrials.gov identifier NCT03004326) studies.